<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="mena-mig01/PMC6961141/results/search/mena-migration/results.xml">
  <result pre="Epidemiology and phenotypes of multiple sclerosis in the Middle East" exact="North Africa" post="(MENA) region YamoutBassem I[], https://orcid.org/0000-0002-9187-5827AssaadWassim[], TamimHani[], MrabetSaloua[], GoueiderRiyad[], American"/>
  <result pre="the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). The Middle East" exact="North Africa" post="(MENA) region falls in the low-to-moderate multiple sclerosis (MS)"/>
  <result pre="We analyzed all data collected from the MENACTRIMS (Middle East" exact="North Africa" post="Committee for Treatment and Research in Multiple Sclerosis) registry"/>
  <result pre="the study. Overall, the clinical phenotype of MS in the" exact="MENA" post="region was not different from the Western phenotype except"/>
  <result pre="clinical course leading to earlier disability. Multiple sclerosis Middle East" exact="North Africa" post="Introduction Multiple sclerosis (MS) is an immune-mediated demyelinating disorder"/>
  <result pre="originating from North America and Europe.1 Most countries from the" exact="MENA" post="(Middle East North Africa) region fall in the low-to-moderate"/>
  <result pre="We reviewed the most relevant epidemiologic studies published in the" exact="MENA" post="region, to determine the prevalence of MS in this"/>
  <result pre="Table 1. Prevalence of multiple sclerosis in the Middle East" exact="North Africa" post="region. n Prevalence (per 100,000) Methodology Kuwait â€ƒAlroughani (2013)"/>
  <result pre="and 2013. The rapid rise of prevalence rates in the" exact="MENA" post="region might be partly due to earlier diagnosis, especially"/>
  <result pre="incidence in the Middle East, such as increased urbanization and" exact="migration" post="from rural areas to large cities. Urbanization is associated"/>
  <result pre="of the world.26 Figure 1. MS Prevalence rates in the" exact="MENA" post="region by decade according to published studies (Each bar"/>
  <result pre="study). Clinical characteristics The clinical characteristics of MS in the" exact="MENA" post="region have been described in isolated studies from single"/>
  <result pre="which included relatively small number of patients. The Middle East" exact="North Africa" post="Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS)"/>
  <result pre="of recruiting patients with MS from different countries in the" exact="MENA" post="region. MSBase is an international observational MS cohort study,"/>
  <result pre="of a more aggressive and disabling MS course in the" exact="MENA" post="region compared with the West. Disease-modifying therapies (DMTs) are"/>
  <result pre="Disease-modifying therapies (DMTs) are available to different degrees in the" exact="MENA" post="region countries. Gulf countries and Lebanon have access to"/>
  <result pre="either not registered or not fully reimbursed by governments. Most" exact="MENA" post="countries, however, have access at least to first-line injectables"/>
  <result pre="that locally manufactured generics, mostly Iranian-produced, are used in the" exact="MENA" post="region. However, as shown in Table 4, they account"/>
  <result pre="the prevalence of MS has been steadily rising in the" exact="MENA" post="region over the past few decades. The clinical phenotype"/>
  <result pre="past few decades. The clinical phenotype of MS in the" exact="MENA" post="region is similar to what has been described in"/>
 </snippets>
</snippetsTree>
